Last updated: August 8, 2026
Benazepril hydrochloride and hydrochlorothiazide is a mature, generic antihypertensive combination marketed originally as Lotensin HCT. Its commercial profile is defined by long-established generic competition, limited pricing power, minimal patent risk, and low standalone revenue visibility. The product remains clinically relevant for hypertension but has limited growth potential because physicians can prescribe the components separately or use newer fixed-dose combinations.
What is benazepril hydrochloride and hydrochlorothiazide?
Benazepril hydrochloride and hydrochlorothiazide combines an angiotensin-converting enzyme inhibitor, benazepril, with the thiazide diuretic hydrochlorothiazide. The FDA-approved product is indicated for hypertension in patients who require combination therapy or who do not achieve adequate control with monotherapy. It is available in three strengths:
| Strength |
Benazepril hydrochloride |
Hydrochlorothiazide |
| Low dose |
5 mg |
6.25 mg |
| Intermediate dose |
10 mg |
12.5 mg |
| High dose |
20 mg |
12.5 mg |
The product is administered once daily. Its therapeutic rationale is conventional: benazepril suppresses the renin-angiotensin system, while hydrochlorothiazide promotes sodium and fluid excretion. The FDA label identifies dose-related risks including hypotension, renal impairment, hyperkalemia, electrolyte abnormalities, and fetal toxicity associated with ACE inhibitors.[1]
Lotensin HCT was developed by Ciba-Geigy, later part of Novartis. The branded product competed in the hypertension market against ACE inhibitor/thiazide combinations such as captopril/hydrochlorothiazide, enalapril/hydrochlorothiazide, lisinopril/hydrochlorothiazide, and quinapril/hydrochlorothiazide.
What is the FDA regulatory status of benazepril hydrochloride and hydrochlorothiazide?
The combination was approved through a conventional new drug application rather than a biologics pathway. The reference product is associated with FDA NDA 019851, covering Lotensin HCT tablets.[2]
The product is a small-molecule oral solid dosage form. It is not a biologic and therefore has no biosimilar pathway. Generic applicants use the abbreviated new drug application, or ANDA, pathway and must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug.
The FDA labeling identifies the following principal regulatory issues:
- ACE inhibitor fetal toxicity and contraindication during pregnancy.
- Angioedema risk.
- Renal function changes and hyperkalemia.
- Hypotension in volume-depleted patients.
- Interaction risks with potassium supplements, potassium-sparing diuretics, lithium, nonsteroidal anti-inflammatory drugs, and renin-angiotensin system inhibitors.
- Electrolyte depletion caused by hydrochlorothiazide.[1]
The combination is a conventional prescription product. It does not have the regulatory characteristics of a new molecular entity, specialty drug, controlled substance, or hospital-administered therapy.
When does benazepril hydrochloride and hydrochlorothiazide lose exclusivity?
Market exclusivity for the combination expired long ago. The underlying active ingredients are also mature compounds with extensive generic use.
| Exclusivity category |
Status |
| New chemical entity exclusivity |
Expired |
| Original branded product exclusivity |
Expired |
| Pediatric exclusivity |
No current commercial significance |
| Orphan-drug exclusivity |
Not applicable |
| Biosimilar exclusivity |
Not applicable |
| Generic substitution |
Established |
| Current commercial protection |
Primarily manufacturing, supply, and distribution economics |
Benazepril itself was disclosed in older patent literature, including U.S. Patent No. 4,410,520. That patent is no longer an effective barrier to generic entry. Hydrochlorothiazide has been generic for decades. Any original formulation or combination patents associated with Lotensin HCT have also passed their enforceable life.
The practical consequence is that market access is no longer controlled by patent expiry dates. It is controlled by ANDA approvals, product availability, wholesaler contracts, formulary status, manufacturing cost, and pharmacy substitution.
What patents protect benazepril hydrochloride and hydrochlorothiazide?
No commercially meaningful blocking patent estate is expected to protect the basic combination in the United States.
Active-ingredient patents
Benazepril is an established ACE inhibitor. Its original composition and related process patents are expired. Hydrochlorothiazide is an older thiazide diuretic whose active-ingredient patent protection expired many years ago.
Formulation patents
The original fixed-dose tablet formulation may have been covered by product-specific claims, but those rights are not expected to prevent current generic competition. Generic tablets are typically approved through ANDAs based on the reference product and do not require ownership of the original formulation patents.
Current commercial differentiation is more likely to involve:
- Tablet manufacturing efficiency.
- Packaging and bottle configurations.
- Supply reliability.
- Contract manufacturing capacity.
- Regulatory compliance.
- Inventory management.
These factors can affect profitability but do not create durable exclusivity comparable to a live pharmaceutical patent.
Method-of-use patents
The hypertension indication is a long-established use of ACE inhibitors and thiazide diuretics. No significant method-of-use patent position is expected to constrain generic prescribing of this combination. A generic applicant could address any listed method-of-use claim through a section viii statement or a corresponding label strategy, where applicable, but the product's principal indication is already genericized.
What is the Orange Book status of Lotensin HCT?
The Orange Book identifies FDA-approved products and, where applicable, patent and exclusivity information. The relevant reference product is Lotensin HCT under NDA 019851.[2]
The commercial significance of the Orange Book listing is limited because:
- The product is an old small-molecule combination.
- Original exclusivity has expired.
- The core active ingredients are widely generic.
- Generic applicants have had a conventional ANDA route.
- No known current patent barrier has preserved branded pricing power.
The Orange Book remains relevant for reference-product designation, therapeutic equivalence, and the identification of approved generic equivalents. It is not expected to support a current branded defense based on unexpired compound protection.
Which companies manufacture generic benazepril hydrochloride and hydrochlorothiazide?
Generic availability has historically involved multiple U.S. and international manufacturers and distributors. Market participants may include vertically integrated generic companies, contract manufacturers, and private-label suppliers. Product availability can change because companies discontinue low-volume strengths, consolidate portfolios, or exit products with weak margins.
For this product, manufacturer competition is more important than brand competition. The principal competitive variables are:
| Variable |
Commercial effect |
| Number of approved suppliers |
More suppliers generally reduce pricing power |
| API sourcing |
Affects cost and shortage exposure |
| Tablet production scale |
Determines unit economics |
| Wholesale contracts |
Influences pharmacy access |
| Product discontinuations |
Can create temporary supply gaps |
| Strength availability |
Affects substitution and prescribing continuity |
| Regulatory observations |
Can disrupt production or approval status |
A generic manufacturer does not need a large sales force to compete. Distribution through wholesalers, pharmacy benefit channels, chain pharmacies, and mail-order pharmacies is usually sufficient.
How strong is the patent estate for benazepril hydrochloride and hydrochlorothiazide?
The patent estate is weak from a commercial-protection perspective. It may contain historical patents, formulation disclosures, manufacturing know-how, trademarks, and regulatory records, but these rights do not create meaningful market exclusivity.
| Patent factor |
Assessment |
| Composition-of-matter protection |
Expired |
| Combination-product protection |
Expired or commercially ineffective |
| Formulation protection |
No known material barrier to generic supply |
| Method-of-use protection |
No meaningful blocking position expected |
| Manufacturing know-how |
Potentially useful operational asset |
| Trademark protection |
Protects branding, not molecule-level competition |
| Freedom to launch generic product |
Established pathway |
The remaining intellectual-property value is therefore defensive or operational. A manufacturer may protect process parameters, quality systems, supplier relationships, or proprietary manufacturing methods, but these assets generally do not prevent competing ANDA products.
Are there Paragraph IV challenges for benazepril hydrochloride and hydrochlorothiazide?
Paragraph IV litigation is unlikely to have current commercial importance for this product. Paragraph IV certifications challenge listed patents as invalid, unenforceable, or not infringed. They are most relevant before patent expiry, when an ANDA filer seeks an early launch.
For an old genericized combination such as benazepril/hydrochlorothiazide:
- Any original listed patents are likely expired.
- ANDA entry does not depend on defeating a current high-value patent.
- No meaningful 30-month stay risk is expected from a historical Lotensin HCT patent dispute.
- Litigation would be more likely to concern manufacturing, supply, labeling, or contractual matters than molecule-level patent enforcement.
A current entrant's principal legal risk is regulatory compliance, not Paragraph IV patent exposure.
What patent litigation affects benazepril hydrochloride and hydrochlorothiazide?
No major active U.S. patent litigation is expected to determine market access for the combination. The product's litigation profile is materially different from newer branded drugs, where Orange Book patents, patent-term extensions, pediatric exclusivity, and settlement agreements can determine launch timing.
Potential disputes could still arise over:
- ANDA approval or FDA administrative action.
- Product liability.
- Manufacturing quality.
- Distribution contracts.
- Antitrust allegations involving supply or contracting.
- False labeling or promotional conduct.
- API sourcing and inspection findings.
These are not equivalent to a live patent estate. They may affect an individual supplier but would not ordinarily restore branded exclusivity across the market.
Are there licensing deals or settlement agreements for the product?
No major current licensing deal or generic settlement agreement is expected to shape the commercial outlook of benazepril hydrochloride and hydrochlorothiazide.
The original product rights were associated with the corporate succession from Ciba-Geigy to Novartis. Any historical commercialization arrangements have limited relevance because generic manufacturers now compete without relying on a current exclusive license from the original innovator.
The absence of a material settlement structure is commercially important. In newer products, a patent settlement can establish a negotiated generic launch date. For this product, launch timing is generally determined by FDA approval, manufacturing readiness, and commercial distribution.
What generic entry risks exist for benazepril hydrochloride and hydrochlorothiazide?
Generic entry risk is already realized rather than prospective. The relevant question is whether additional suppliers can enter profitably and whether existing suppliers will remain in the market.
Generic launch scenarios
| Scenario |
Likely market effect |
| Additional ANDA approval |
More supply and lower average pricing |
| Supplier withdrawal |
Temporary shortages and potential price recovery |
| Manufacturing disruption |
Wholesaler allocation and pharmacy substitutions |
| Formulary preference for low-cost products |
Increased generic share |
| Brand re-entry |
Limited probability without a clear price or supply advantage |
| New fixed-dose competitor |
Minimal clinical differentiation unless it offers a meaningful dosage or packaging advantage |
The product's low technical complexity lowers entry barriers, but its mature market and low pricing can also reduce the incentive to add capacity. This produces a common generic-market tension: entry is easy in regulatory terms, but sustainable profits may be modest.
How does benazepril/hydrochlorothiazide compare with competing antihypertensive combinations?
Benazepril/hydrochlorothiazide competes with both other ACE inhibitor/thiazide combinations and newer treatment classes.
| Product class |
Competitive position |
| Benazepril/hydrochlorothiazide |
Mature, low-cost ACE inhibitor/thiazide combination |
| Lisinopril/hydrochlorothiazide |
Broad generic availability and stronger prescribing familiarity |
| Enalapril/hydrochlorothiazide |
Established generic alternative |
| Losartan/hydrochlorothiazide |
ARB-based option, often selected when ACE inhibitor cough is a concern |
| Valsartan/hydrochlorothiazide |
Generic ARB combination |
| Amlodipine/benazepril |
Calcium-channel blocker/ACE inhibitor combination |
| Single-agent therapy |
Often used before fixed-dose escalation |
| Separate generic components |
Flexible dosing and often low acquisition cost |
Lisinopril/hydrochlorothiazide and losartan/hydrochlorothiazide generally have broader market recognition. Benazepril/hydrochlorothiazide can remain relevant where clinicians value continuity, patient response, or existing formulary placement.
The main commercial disadvantage is therapeutic substitutability. A prescriber can choose another ACE inhibitor/thiazide combination, an ARB/thiazide product, or separate tablets. That limits the ability of any single manufacturer to raise price.
What is the financial trajectory of benazepril hydrochloride and hydrochlorothiazide?
Standalone revenue data are generally unavailable because manufacturers report broader portfolios rather than sales for this individual generic combination. The financial trajectory is therefore best assessed through market structure rather than a reported product-level revenue series.
Historical trajectory
The product likely generated its highest economic value during the branded period, when Lotensin HCT benefited from prescription branding, physician promotion, and limited direct generic competition. After exclusivity expired, the economic model changed:
- Branded pricing declined.
- Generic substitution increased.
- Multiple manufacturers competed for pharmacy and wholesaler volume.
- Revenue shifted from brand economics to high-volume, low-margin supply.
- Product-level reporting became limited or disappeared within corporate portfolio disclosures.
Current trajectory
The current market is likely characterized by:
- Low average selling prices.
- High generic substitution.
- Limited promotional spending.
- Stable demand linked to chronic hypertension treatment.
- Low revenue growth from volume alone.
- Margin sensitivity to API and manufacturing costs.
- Potential intermittent supply-driven price increases.
- Limited value from patent litigation or licensing.
Revenue exposure
For an innovator, direct revenue exposure is likely immaterial compared with newer cardiovascular, oncology, immunology, and specialty products. For a generic manufacturer, the product may contribute incremental revenue but is unlikely to be a strategic growth driver unless the company has:
- A low-cost manufacturing platform.
- Reliable API supply.
- A large retail distribution network.
- A portfolio strategy centered on mature oral solids.
- An opportunity to capture volume after a competitor withdrawal.
What manufacturing and intellectual-property barriers remain?
Manufacturing barriers are moderate operationally but low legally. The active ingredients are established, and the dosage form is a conventional tablet. The principal execution requirements are:
- Consistent API quality.
- Control of dissolution and assay specifications.
- Stability across shelf life.
- Validated tablet compression and coating processes.
- Compliance with current good manufacturing practice.
- Reliable packaging and serialization.
- Bioequivalence documentation.
- FDA inspection readiness.
Hydrochlorothiazide is inexpensive and widely sourced. Benazepril hydrochloride may represent a smaller-volume API with fewer qualified suppliers than the most common ACE inhibitors. That can create procurement risk even when the finished dosage form is technically simple.
The most relevant barriers are therefore supply-chain and quality-system barriers, not patent rights.
What geographic coverage applies to the product?
The product's core patent barriers have expired in the major pharmaceutical markets. Generic availability and regulatory status vary by jurisdiction.
- In the United States, ANDA-approved generic products compete under FDA therapeutic-equivalence rules.
- In the European Union, national and decentralized authorization systems govern generic entry.
- In Canada and other regulated markets, equivalent generic approval pathways apply.
- In lower-income markets, fixed-dose combinations may be available through local registration or procurement channels, but product labeling and manufacturer participation vary.
Global commercial value is constrained by widespread generic competition. Geographic opportunities are more likely to arise from supply contracts, public procurement, or local shortages than from exclusive intellectual-property rights.
Key Takeaways
- Benazepril hydrochloride and hydrochlorothiazide is a mature ACE inhibitor/thiazide combination marketed originally as Lotensin HCT.
- FDA approval is associated with NDA 019851, and generic entry is established.
- Original composition, combination, and formulation protections no longer provide meaningful market exclusivity.
- The product has no biosimilar risk because it is a small-molecule oral tablet.
- Paragraph IV litigation and patent settlements are unlikely to determine current market access.
- Financial value has shifted from branded pricing to low-margin generic volume.
- Standalone revenue is generally not disclosed by manufacturers.
- Competitive performance depends on supply reliability, manufacturing cost, wholesaler access, and formulary placement.
- The greatest commercial risk is supplier withdrawal or manufacturing disruption, not patent infringement.
- New growth is unlikely without a supply shortage, portfolio acquisition, or distribution advantage.
FAQs
Is benazepril hydrochloride and hydrochlorothiazide still patented?
The original patent protection is expired or commercially ineffective. Current generic access is not expected to be blocked by a live composition-of-matter patent.
Is Lotensin HCT still commercially important?
It remains clinically recognized, but its commercial importance is limited by generic substitution and competition from other ACE inhibitor/thiazide and ARB/thiazide combinations.
Can a generic company launch benazepril/hydrochlorothiazide without a patent settlement?
Yes. Because the product is long genericized, launch generally depends on FDA approval and commercial readiness rather than a negotiated patent-settlement date.
Does benazepril/hydrochlorothiazide have biosimilar competition?
No. Biosimilars apply to biological products. Benazepril/hydrochlorothiazide is a conventional small-molecule tablet and competes through ANDAs.
What could increase the price of generic benazepril/hydrochlorothiazide?
A temporary price increase could result from manufacturer withdrawals, API shortages, FDA manufacturing actions, wholesaler allocation, or a sudden reduction in available strengths. Durable price expansion is unlikely in a multi-supplier market.
References
- U.S. Food and Drug Administration. (n.d.). Lotensin HCT: Benazepril hydrochloride and hydrochlorothiazide prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Lotensin HCT, NDA 019851. https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
- U.S. Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/
- U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda
